MenBvac

MenBvac is an outer membrane vesicle vaccine developed to prevent systemic meningococcal disease caused by serogroup B Neisseria meningitidis. Clinical studies have demonstrated that a four-dose regimen (three primary doses 6 weeks apart followed by a fourth booster dose a year later) provides good immunogenicity with prolonged persistence and increased cross-reactivity of functional antibodies. The vaccine has shown an acceptable safety profile with mild to moderate local and systemic reactions.

Brand names

MenBvac

Other names

MenBVac vaccineOuter membrane vesicle meningococcal B vaccineOMV-based meningococcal B vaccine